FibroGen stock trades at USD 6.94 after Kyntra Bio rebrand
Published on 09/28/2026 at 14:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
FibroGen stock was trading at USD 6.94 on Nasdaq on September 28, 2026, after the issuer completed its rebrand to Kyntra Bio. According to StockTitan on January 7, 2026, the former FGEN symbol changed to KYNB at the market open on January 8, 2026.
Lake Street sets USD 41.00 target
Lake Street initiated coverage with a Buy rating and a USD 41.00 price target on September 17, 2026, according to GuruFocus. The target lies 490.78 percent above the September 28, 2026 Nasdaq price, making the analyst view the clearest valuation reference for the renamed company.
Q2 earnings show a sharp swing
Kyntra Bio reported USD 11.97 million of net income and diluted earnings per share of USD 2.96 for the second quarter of 2026, while revenue was USD -1.50 million, according to TradingView. The prior quarter showed a net loss of USD 15.13 million, so the reported earnings swing was USD 27.10 million between Q1 and Q2 2026.
The operating picture remains tied to clinical development rather than recurring product sales. Kyntra Bio is advancing programs in oncology and rare diseases, while its investor calendar lists the second-quarter 2026 conference call on August 13, 2026, as reported on the company investor page.
Stock stays below yearly high
The September 28, 2026 price of USD 6.94 sits within a 52-week range of USD 4.85 to USD 12.60 reported for the Nasdaq listing on September 27, 2026. It is 44.92 percent below the 52-week high, leaving the analyst target and the next clinical milestones as the main numerical reference points for the renamed business.
Next results date is November 9
TradingView lists November 9, 2026, as the next earnings date. FibroGen stock therefore represents a legacy search term for the Nasdaq-listed company now operating under the Kyntra Bio name and KYNB ticker.
FibroGen market snapshot
- Company: Kyntra Bio, Inc.
- Ticker: KYNB
- Trading venue: Nasdaq
- Price as of September 28, 2026: USD 6.94
- 52-week range: USD 4.85-USD 12.60 as of September 27, 2026
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 9, 2026
